Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

RELATED NEWS
Trade PPHM now with 

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM: Quote) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

Click here to receive FREE breaking news email alerts for Peregrine Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved sharply lower over the course of the trading day on Wednesday, adding to the modest weakness seen in the two previous sessions. With the losses on the day, the major averages fell to their lowest closing levels in over a month. Democrats have climbed into the lead on a generic ballot, according to the results of a new CNN/ORC International poll, although the results may not be as positive for the party as they first appear. With spending on private and public construction both showing notable decreases, the Commerce Department released a report on Wednesday showing an unexpected drop in U.S. construction spending in the month of August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.